Why the study?
Does nifekalant alter electrophysiologic properties to facilitate termination of typical atrial flutter?
Does nifekalant alter electrophysiologic properties to facilitate termination of typical atrial flutter?
Nifekalant facilitates the termination of typical atrial flutter by increasing the atrial effective refractory period and abolishing a fully excitable gap.
Nifekalant-associated AFL termination in this cohort; leaves open its comparative efficacy and safety versus standard agents in randomized trials.
Background Little is known about the effect of nifekalant, a pure I Kr ‐selective blocker, on typical atrial flutter (AFL) and its termination mechanism. Methods The effects of nifekalant on AFL were elucidated in 17 patients. During AFL, the conduction time from the lateral to septal cavotricuspid isthmus (IS) and that through the reminder of the right atrium (nIS); AFL‐cycle length (CL) variability, which was quantified by the standard deviation; and the maximum difference in AFL‐CL were measured before and after administration of nifekalant (0.2–0.3 mg/kg). A single extrastimulus was delivered from the lateral cavotricuspid isthmus to elucidate the resetting response curves and atrial effective refractory period (AERP) before and after administration of nifekalant. Results There was no significant difference in AFL‐CL, IS, and nIS before and after nifekalant; however, AERP was increased after nifekalant (155 ± 22 ms vs 184 ± 32 ms, P < 0.001). The standard deviation and the maximum difference in AFL‐CL were both increased after nifekalant (1.7 ± 0.7 ms vs 3.6 ± 2.3 ms, P < 0.001 and 4.1 ± 1.9 ms vs 8.5 ± 5.2 ms, P < 0.001). The total excitable gap decreased (94 ± 17 ms vs 66 ± 21 ms, P < 0.001) with rightward shift of the resetting response curves and loss of full excitability after nifekalant. In 11 patients (65%), AFL was terminated spontaneously (n = 7) or by a single extrastimulus (n = 4), which was not observed before nifekalant. Termination was associated with orthodromic block in the cavotricuspid isthmus in all patients. Conclusions Nifekalant increases AERP and AFL‐CL variability by abolishing a fully excitable gap, without prolongation of AFL‐CL. These unique effects facilitate the termination of AFL.
No takes yet. Share an insight, caveat, or question.
Yamabe et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: